Vitamin B6 Metabolism Determines T Cell Anti-Tumor Responses.
View / Open Files
Authors
Bargiela, David
Cunha, Pedro P
Veliça, Pedro
Barbieri, Laura
Rundqvist, Helene
Johnson, Randall S
Publication Date
2022-02-17Journal Title
Frontiers in immunology
ISSN
1664-3224
Volume
13
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Bargiela, D., Cunha, P. P., Veliça, P., Foskolou, I. P., Barbieri, L., Rundqvist, H., & Johnson, R. S. (2022). Vitamin B6 Metabolism Determines T Cell Anti-Tumor Responses.. Frontiers in immunology, 13 https://doi.org/10.3389/fimmu.2022.837669
Description
Funder: Knut och Alice Wallenbergs Stiftelse
Funder: Vetenskapsrådet
Funder: Barncancerfonden
Funder: Cancerfonden
Abstract
Targeting T cell metabolism is an established method of immunomodulation. Following activation, T cells engage distinct metabolic programs leading to the uptake and processing of nutrients that determine cell proliferation and differentiation. Redirection of T cell fate by modulation of these metabolic programs has been shown to boost or suppress immune responses <i>in vitro</i> and <i>in vivo</i>. Using publicly available T cell transcriptomic and proteomic datasets we identified vitamin B6-dependent transaminases as key metabolic enzymes driving T cell activation and differentiation. Inhibition of vitamin B6 metabolism using the pyridoxal 5'-phosphate (PLP) inhibitor, aminoxyacetic acid (AOA), suppresses CD8+ T cell proliferation and effector differentiation in a dose-dependent manner. We show that pyridoxal phosphate phosphatase (PDXP), a negative regulator of intracellular vitamin B6 levels, is under the control of the hypoxia-inducible transcription factor (HIF1), a central driver of T cell metabolism. Furthermore, by adoptive transfer of CD8 T cells into a C57BL/6 mouse melanoma model, we demonstrate the requirement for vitamin B6-dependent enzyme activity in mediating effective anti-tumor responses. Our findings show that vitamin B6 metabolism is required for CD8+ T cell proliferation and effector differentiation <i>in vitro</i> and <i>in vivo</i>. Targeting vitamin B6 metabolism may therefore serve as an immunodulatory strategy to improve anti-tumor immunotherapy.
Keywords
Metabolism, Hypoxia, Immunotherapy, Vitamin B6, Cd8+ Lymphocytes
Sponsorship
Wellcome Trust (211143/Z/18/Z)
Identifiers
35251031, PMC8891565
External DOI: https://doi.org/10.3389/fimmu.2022.837669
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335854
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.